Envision Financial Planning’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$98.6K Hold
10,450
– – 0.03% 53
2026
Q2
$91.5K Hold
10,450
– – 0.03% 55
2026
Q1
$80.2K Hold
10,450
– – 0.03% 51
2025
Q4
$20.7K Hold
10,450
– – 0.01% 47
2025
Q3
$25.7K Hold
10,450
– – 0.01% 45
2025
Q2
$27.6K Buy
+10,450
New +$28.1K 0.01% 49

Other funds holding IBRX

Envision Financial Planning's IBRX Position: Q3 2026 in Review

Envision Financial Planning held its ImmunityBio (IBRX) position steady in Q3 2026 at 10,450 shares worth $98.6K. The position accounts for 0.03% of the portfolio, ranked #53.

Envision Financial Planning first reported a position in IBRX in Q2 2025 and has held it in 6 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Envision Financial Planning held 10,450 shares of ImmunityBio worth $98.6K as of Q3 2026.
  • Envision Financial Planning left its ImmunityBio share count unchanged in Q3 2026.
  • ImmunityBio made up 0.03% of Envision Financial Planning's portfolio in Q3 2026, its #53 holding.
  • Envision Financial Planning first reported a position in ImmunityBio in Q2 2025 and has held it in 6 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Envision Financial Planning's 13F filing for Q3 2026, filed 16 Nov 2026.